Prenetics Global Limited (NASDAQ: PRE) will report its financial results for the second quarter of 2026, ended June 30, 2026, before market open on Tuesday, August 18, 2026. The announcement confirms the timing for investors seeking updates on the consumer health company’s performance and strategy. Prenetics, parent of the AI-native direct-to-consumer wellness brand IM8 co-founded by David Beckham, is also altering its standard disclosure format to provide shareholders with a more comprehensive view of its operations.

Beginning with this quarter, the company will replace its traditional earnings press release with a detailed shareholder letter and an accompanying investor deck. These documents will be published on its investor relations website at https://ir.prenetics.com/ . This shift aims to offer deeper insights into the company’s performance, strategic direction, and outlook compared to standard regulatory filings.

On the same day, August 18, 2026, management will host a live-streamed earnings event on Stocktwits starting at 8:30 a.m. Eastern Time. During this session, executives will discuss the quarterly results and hold a question-and-answer period. Investors can access the live stream at https://stocktwits.com/symbol/PRE . Those wishing to submit questions in advance may email investors@prenetics.com . A replay of the event will be available on the company’s investor relations website following the broadcast.

Upcoming Investor Conferences

Prenetics management has scheduled participation in several upcoming investor conferences to engage with analysts and shareholders. The schedule includes appearances at major growth and sector-specific events across Boston and New York City.

The fireside chat at the Canaccord Genuity conference will be available for viewing via a dedicated link and on the company’s investor relations website. Investors interested in scheduling one-on-one meetings with management can contact Investor Relations at PRE@mzgroup.us or reach out through their conference representatives.

Company Background

Prenetics Global Limited operates as a leading consumer health company focused on advancing human health and longevity. Its flagship brand, IM8, is positioned as a premium daily nutrition system anchored by Daily Ultimate Essentials, a 90-ingredient formula that is NSF Certified for Sport and clinically studied. IM8 has surpassed $200 million in annualized run-rate revenue within 18 months of launch, shipping to 46 countries and delivering approximately 200,000 servings daily. The brand’s ambassador and equity-partner roster includes David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty, and Inter Miami CF.

Benchmark analyst Bill Sutherland has maintained a Buy rating on Prenetics Global and raised the price target to $40 from $30. The revised target indicates a more optimistic outlook for the company's stock performance.

Rating and Target Details

The decision to upgrade the price target comes as Benchmark reaffirms its positive stance on Prenetics Global. The new target of $40 represents a significant increase from the previous $30 level.

Prenetics Global is listed on NASDAQ under the ticker symbol PRE.